Imunon Inc - IMNN Total Company Value-to-Revenue Ratio

Imunon Inc (IMNN) - corporate logo

The EV/Sales chart on GURU.Markets illustrates the ratio of Imunon, Inc. (IMNN) market value to operating income excluding debt, where the 0.00 mark serves as a key metric. A unique genetic material delivery method provides the company with significant pricing power. Diversification of the cancer and infection vaccine portfolio minimizes risks. The strategy relies on expanding clinical trials and securing government grants.

Imunon Inc (IMNN) Enterprise Value-to-Revenue Ratio: for the period 11/23/2025 - 11/20/2026

Imunon Inc - analytical breakdowns and key metrics (IMNN)

- market price and analyst price targets:
Initial company analysis:Imunon Inc, IMNN
Finished products of Imunon

This indicator measures the enterprise value of the business, including net debt relative to sales volume, allowing for an assessment of revenue capitalization efficiency without distortions from financial leverage. By analyzing the EV/Revenue multiple, an investor can benchmark the current valuation of Imunon, Inc. (IMNN) against the risks of R&D expenditures for cancer immunotherapy development, where the company's value is driven by the potential of clinical trials while maintaining sufficient liquidity.

Competitor analysis for Imunon, Inc.

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple